Moderate
Elana Gotkine
October 5, 2024
For patients with moderate-to-severe atopic dermatitis (AD), lebrikizumab has long-term efficacy, according to a study presented at...
Elisabeth Mahase
August 15, 2024
The National Institute for Health and Care Excellence has recommended linzagolix (marketed as Yselty) for moderate to...
Roni Caryn Rabin
August 12, 2024
Even light drinking was associated with an increase in cancer deaths among older adults in Britain, researchers...